$6.13 -0.01 (-0.16%)
2/13/2012 3:59 PM

Exelixis, Inc. (NASDAQ:EXEL)

CAPS Rating: 4 out of 5

A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.

Recs

24
Player Avatar ResearchLover (< 20) Submitted: 3/12/2008 12:11:10 PM : Outperform Start Price: $5.29 EXEL Score: +70.82

I am a molecular biologist and have been at presentations for mid/late stage compounds, such as PPAR ligands, that EXEL is developing. They have the expertise to develop successful compounds. And they are at a bargain basement price now. If you need a signal to enter, wait for insider buying, which hasn't occured lately as of 3/10/08.

Report this Post Add Comment

Featured Broker Partners


Advertisement